# Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

> **NCT01002807** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 15 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Metformin XR
- **DRUG:** Glucophage

## Key facts

- **NCT ID:** NCT01002807
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002807, "Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01002807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*